DP-b99 (D-Pharm).
DP-b99 is a derivative of the calcium chelator BAPTA that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft. By March 2003, phase II clinical trials in acute stroke and traumatic brain injury were ongoing.
Pharmacokinetics & Metabolism Laboratory, College of Pharmacy, Burbridge Building, Dalhousie University, Halifax, NS B3H-3J5, Canada. pollen.yeung@dal.ca
Pollen K F
PK
Yeung
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D001026:Coronary Artery Bypass / Q000009:adverse effects; D006259:Craniocerebral Trauma / Q000188:drug therapy; D004533:Egtazic Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D009422:Nervous System Diseases / Q000188:drug therapy / Q000209:etiology; D018696:Neuroprotective Agents / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
C428064:DP-b99; D018696:Neuroprotective Agents; D004533:Egtazic Acid